Infographic: Efficacy and Safety of High-Dose Intravitreal Aflibercept 8 mg in Patients with Treatment-Naïve Neovascular Age-Related Macular Degeneration: Week 96 Results from the Phase 3 PULSAR Trial
Jean-François Korobelnik, Sergio Leal, Paolo Lanzetta, on behalf of the Korean Familial Hypercholesterolemia (KFH) Registry Investigators et autres
Fig. 1 The alternative text for this image may have been generated using AI. Full size image In the phase 3 PULSAR trial, aflibercept 8 mg demonstrated similar visual and anatomic improvements with extended dosing intervals and a similar safety profile to …
fr, ch, it, ar, au, at, bg, br, cn, ca, sk, cz, us, ee, ge, hu, il (code pays fourni par la source)